EA201891258A1 - Новые производные диаминопиридина - Google Patents

Новые производные диаминопиридина

Info

Publication number
EA201891258A1
EA201891258A1 EA201891258A EA201891258A EA201891258A1 EA 201891258 A1 EA201891258 A1 EA 201891258A1 EA 201891258 A EA201891258 A EA 201891258A EA 201891258 A EA201891258 A EA 201891258A EA 201891258 A1 EA201891258 A1 EA 201891258A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
present
diaminopyridine derivatives
compounds
methods
Prior art date
Application number
EA201891258A
Other languages
English (en)
Other versions
EA035899B1 (ru
Inventor
Гебхард Тома
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201891258A1 publication Critical patent/EA201891258A1/ru
Publication of EA035899B1 publication Critical patent/EA035899B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении описаны новые производные диаминопиридина, способные модулировать JAK. Настоящее изобретение также относится к фармацевтическим композициям, содержащим эти новые соединения, способам применения указанных соединений для лечения разных заболеваний или нарушений, восприимчивых к модулированию JAK, и способам получения соединений, описанных в настоящем изобретении.
EA201891258A 2015-11-26 2016-11-24 Производные диаминопиридина в качестве ингибиторов jak EA035899B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26
PCT/IB2016/057105 WO2017089985A1 (en) 2015-11-26 2016-11-24 Diamino pyridine derivatives

Publications (2)

Publication Number Publication Date
EA201891258A1 true EA201891258A1 (ru) 2018-10-31
EA035899B1 EA035899B1 (ru) 2020-08-28

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891258A EA035899B1 (ru) 2015-11-26 2016-11-24 Производные диаминопиридина в качестве ингибиторов jak

Country Status (35)

Country Link
US (3) US10570096B2 (ru)
EP (2) EP3380465B1 (ru)
JP (1) JP6634157B2 (ru)
KR (1) KR102097878B1 (ru)
CN (2) CN112851578A (ru)
AU (1) AU2016359438B2 (ru)
BR (1) BR112018009540A2 (ru)
CA (1) CA3005159A1 (ru)
CL (1) CL2018001370A1 (ru)
CO (1) CO2018005354A2 (ru)
CR (1) CR20180285A (ru)
CU (1) CU24506B1 (ru)
CY (1) CY1123543T1 (ru)
DK (1) DK3380465T3 (ru)
DO (1) DOP2018000127A (ru)
EA (1) EA035899B1 (ru)
EC (1) ECSP18041731A (ru)
ES (2) ES2829052T3 (ru)
HK (1) HK1253530A1 (ru)
HR (1) HRP20201662T1 (ru)
HU (1) HUE052345T2 (ru)
IL (1) IL259360B (ru)
LT (1) LT3380465T (ru)
MX (1) MX2018006495A (ru)
MY (1) MY195905A (ru)
PE (1) PE20181071A1 (ru)
PH (1) PH12018501019A1 (ru)
PL (2) PL3380465T3 (ru)
PT (2) PT3380465T (ru)
RS (1) RS60946B1 (ru)
RU (2) RU2730007C2 (ru)
SA (1) SA518391657B1 (ru)
SG (1) SG11201803760VA (ru)
SI (1) SI3380465T1 (ru)
WO (1) WO2017089985A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3380465T3 (pl) * 2015-11-26 2021-01-25 Novartis Ag Pochodne diaminopirydyny
BR112021013377A2 (pt) 2019-01-11 2021-09-14 Novartis Ag Inibidores de lta4h para o tratamento de hidradenite supurativa
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
PL2134689T3 (pl) 2007-03-16 2014-10-31 Scripps Research Inst Inhibitory kinazy ognisk adhezyjnych
US20110230467A1 (en) 2008-11-21 2011-09-22 Astellas Pharma Inc. 4,6-diaminonicotinamide compound
AU2009320683B2 (en) 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2565193B1 (en) * 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR20150068484A (ko) 2012-10-19 2015-06-19 에프. 호프만-라 로슈 아게 Syk 억제제
AU2013341185B2 (en) * 2012-11-08 2017-07-13 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
MX2015005562A (es) * 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa.
EP2922846B1 (en) * 2012-11-08 2018-10-03 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
AU2014339897A1 (en) 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
CA2969590A1 (en) 2014-12-03 2016-06-09 Rxi Pharmaceuticals Corporation Methods for the treatment of alopecia areata utilizing gene modulation approaches
PL3380465T3 (pl) * 2015-11-26 2021-01-25 Novartis Ag Pochodne diaminopirydyny

Also Published As

Publication number Publication date
PE20181071A1 (es) 2018-07-04
EP3757097B1 (en) 2022-03-30
HUE052345T2 (hu) 2021-04-28
PL3380465T3 (pl) 2021-01-25
AU2016359438B2 (en) 2019-05-02
CA3005159A1 (en) 2017-06-01
CL2018001370A1 (es) 2018-07-27
SG11201803760VA (en) 2018-06-28
US20200140386A1 (en) 2020-05-07
ECSP18041731A (es) 2018-06-30
RU2730007C2 (ru) 2020-08-14
EA035899B1 (ru) 2020-08-28
DOP2018000127A (es) 2018-10-31
CN112851578A (zh) 2021-05-28
MX2018006495A (es) 2018-08-15
EP3380465A1 (en) 2018-10-03
KR20180067681A (ko) 2018-06-20
KR102097878B1 (ko) 2020-04-06
EP3380465B1 (en) 2020-08-05
PT3380465T (pt) 2020-10-23
SI3380465T1 (sl) 2020-11-30
ES2829052T3 (es) 2021-05-28
ES2916582T3 (es) 2022-07-01
EP3757097A1 (en) 2020-12-30
RU2018122953A3 (ru) 2020-01-29
RU2018122953A (ru) 2019-12-26
HRP20201662T1 (hr) 2020-12-25
IL259360B (en) 2021-05-31
AU2016359438A1 (en) 2018-05-31
CU20180044A7 (es) 2018-10-04
DK3380465T3 (da) 2020-10-26
CN108349937B (zh) 2021-02-09
US10570096B2 (en) 2020-02-25
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
LT3380465T (lt) 2020-11-10
CY1123543T1 (el) 2022-03-24
PL3757097T3 (pl) 2022-07-25
JP6634157B2 (ja) 2020-01-22
BR112018009540A2 (pt) 2018-11-06
WO2017089985A1 (en) 2017-06-01
HK1253530A1 (zh) 2019-06-21
JP2019503343A (ja) 2019-02-07
CO2018005354A2 (es) 2018-05-31
MY195905A (en) 2023-02-27
CR20180285A (es) 2018-07-16
IL259360A (en) 2018-07-31
SA518391657B1 (ar) 2021-02-22
US20180354904A1 (en) 2018-12-13
CN108349937A (zh) 2018-07-31
RS60946B1 (sr) 2020-11-30
CU24506B1 (es) 2021-04-07
PH12018501019A1 (en) 2018-12-17
US11274080B2 (en) 2022-03-15
US20220177432A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201790806A1 (ru) Иммунорегулирующие средства
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
EA201691940A1 (ru) Новые соединения
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
EA201890245A1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201990400A1 (ru) Соединения и композиции и их применение
EA202092627A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
TW201713686A (en) Methods for preparing modified von Willebrand factor

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ TM